Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6641356 | 0.91 | EDNRA (0.86) | EDNRAEDNRB | |
| Edonentan SCHEMBL29742313 | 0.89 | EDNRA (1.00) | EDNRAEDNRB | |
| Edonentan SCHEMBL1651069 | 0.89 | EDNRA (1.00) | EDNRAEDNRB | |
| SCHEMBL6638555 | 0.82 | EDNRB (0.92) | EDNRAEDNRB | |
| SCHEMBL6703895 | 0.82 | EDNRA (0.71) | EDNRAEDNRB | |
| SCHEMBL26552022 | 0.81 | EDNRA (0.76) | EDNRAEDNRB | |
| SCHEMBL6642915 | 0.80 | EDNRB (0.79) | EDNRAEDNRB | |
| SCHEMBL6642249 | 0.80 | EDNRB (1.00) | EDNRAEDNRB | |
| SCHEMBL6963011 | 0.79 | EDNRA (0.68) | EDNRAEDNRB | |
| SCHEMBL6641551 | 0.79 | EDNRB (0.83) | EDNRAEDNRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11738007-B2 | Treatment of glaucoma using endothelin receptor antagonists | PERFUSE THERAPEUTICS, INC. (US) | 2023-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11738007-B2 | Treatment of glaucoma using endothelin receptor antagonists | EDNRA, EDNRB, FLT1 | EDNRA 1/4885EDNRB 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.